GEN Exclusives

More »

Legal Affairs

More »
Jun 1, 2010 (Vol. 30, No. 11)

Are Biotech Inventions Still Protectable?

ACLU v. Myriad Decision May Stimulate New Protection Strategies for Industry

  • Lawsuit

    Last year, the ACLU and others brought the debate over gene patenting to court. On May 12, 2009, they filed a lawsuit against Myriad Genetics, the USPTO, and the University of Utah, challenging the USPTO’s authority to issue patents that relate to products of nature and the legitimacy of claims issued to Myriad Genetics that relate to isolated DNA encoding the breast cancer markers BRCA1 and BRCA2 and to methods of detecting alterations in BRCA1 gene sequence (i.e., to diagnose cancer).

    The District Court has now declared that both genes and methods of detecting gene sequences are not patentable subject matter. Relying mostly on Supreme Court decisions that predate Diamond v. Chakrabarty, the court articulated a test that patentable subject matter must be “markedly different” from a product of nature and concluded that isolated DNA including cDNA is not “markedly different” from natural DNA.

    Interestingly, the court made it clear that DNA’s unique qualities as a physical embodiment of information was critical in its decision. The court stated that its conclusion was “driven by the overriding importance of DNA’s nucleotide sequence to both its natural biological function, as well as the utility associated with DNA in its isolated form” and “[t]he preservation of this defining characteristic of DNA in its native and isolated forms mandates the conclusion that the challenged composition claims are directed to unpatentable products of nature.” 

    The court also held that diagnostic and screening methods that utilize gene sequence information are also not patentable, even though Mother Nature clearly did not design the steps of those methods. This part of the decision was ostensibly grounded in recent case law (Bilski) articulating technical requirements for writing patent claims to methods, but it is clear that the overriding problem with the patents was that they claimed the use of gene sequences.

  • Implications of ACLU Decision

    The decision, as it stands, could have far-reaching implications in the world of biotech patenting. The expansive language and generalized analysis in the decision could be interpreted to invalidate thousands of biotech patents that currently protect biologic products or diagnostic methods. Moreover, since most biotech inventions rely to some extent on genetic information or its analysis, the decision casts a shadow of uncertainty over the entire industry.

    However, panic is premature. Once appealed, the Federal Circuit is likely to reverse or limit the decision. Indeed, it would be difficult to reconcile some of the language of the ACLU decision with long-standing (and recently reaffirmed) decisions by the Federal Circuit and Supreme Court. Appellate courts are also typically cautious about taking action that goes directly against long-standing industry practice.

    However, everyone in the biotech and pharmaceutical communities should take notice of the trend toward limiting patent scope in the industry. Various decisions, from Bilski to Ariad, all emphasize that patents should be awarded for precise, focused, and complete inventions. The days of sweeping patent coverage for fundamental inventions may well have passed. If the ACLU decision stands, even patents on specific biotech products may be unavailable.

    Does this catastrophic scenario mean the industry will collapse? No. While biotech patents are being questioned, new forms of protection for biotech products are being developed. The recent healthcare reform legislation includes a 12-year exclusivity provision for innovator biologics. Such protection is very different from a patent but certainly provides significant commercial incentive and value. Congress clearly understands the importance of protecting biotech products. We believe that the courts understand this too.

    At the end of the day, it is likely that the worst of the ACLU decision will be reversed or redirected. Some aspects of it, perhaps setting heightened standards for defining a product as “manipulated by the hand of man” and, therefore, distinguished from products of nature, may well survive.

    However, more practical and product-orientated patent policies may very well promote development in biotechnology. And there’s nothing like a common enemy to stimulate collaboration within an industry. If this ACLU decision can act as the biotech industry bad guy and stimulate greater innovation, what seems like a doomsday ending might turn out to be a new beginning.


Readers' Comments

Posted 01/25/2011 by Rohit A

<p><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:PunctuationKerning />null
<w:ValidateAgainstSchemas />null
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:Compatibility>
<w:BreakWrappedTables />null
<w:SnapToGridInCell />null
<w:WrapTextWithPunct />null
<w:UseAsianBreakRules />null
<w:DontGrowAutofit />null
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]-->
<!--
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-parent:"";
margin:0in;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";}
@page Section1
{size:8.5in 11.0in;
margin:1.0in 1.25in 1.0in 1.25in;
mso-header-margin:.5in;
mso-footer-margin:.5in;
mso-paper-source:0;}
div.Section1
{page:Section1;}
-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]-->
That was very informative and well written. I look forward
for further posts from you. Recently I happened to read an article on Patentablity of biotech inventions in Europe which I felt quite interesting and informative. I would like to bring
your kind attention to that post. Below mentioned is an excerpt of the
mentioned article.The discussion with respect to patentability of biotech inventions in
Europe has been limited to the European Patent Convention (EPC). As
per the European Patent Convention, any invention is patentable unless
it falls within the list of excluded inventions. According to Article
52 of EPC, any invention irrespective of the technology to which it
belongs can be considered as patentable subject matter so long as it is
new, inventive and has an industrial applicability and does not fall
within the list of excluded inventions provided in Article 53 of the
EPC.

Along with inventions contrary to public order or morality, the list of
exclusions also include plant and animal varieties, essential biological
processes for the production of plants and animals and methods of
treatment. The EU Biotechnology Directive passed in 1998 clarified the
scope of patentability of biotech inventions to a large extent. Though ... To read more, click here http://www.sinapseblog.com/2011/01/patentability-of-biotech-inventions-in.html#more
</p>

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?